SCHEMBL30946164

SCHEMBL30946164

CC1CN(C(=O)NCc2cc3cc(Cl)c(OCc4cscn4)cc3[nH]2)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ EGFR P00533 2/20 0.34
▸ MGLL Q99685 1/20 0.33
▸ ERBB2 P04626 1/20 0.33
▸ ACACB O00763 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ IDH1 O75874 4/20 0.31
▸ RHEB Q15382 1/20 0.31
▸ DPP4 P27487 1/20 0.31
▸ FLT1 P17948 1/20 0.31
▸ EPHA2 P29317 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ EPHB4 P54760 1/20 0.31
▸ CYP2C9 P11712 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ EPHX2 P34913 1/20 0.30
▸ CYP2J2 P51589 1/20 0.30
▸ NMT1 P30419 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27247726 1.00 GRM5 (0.34) GRM5SMN1; SMN2EGFRMGLLERBB2
SCHEMBL27247173 0.92 SMN1; SMN2 (0.35) GRM5SMN1; SMN2EGFRMGLLERBB2
SCHEMBL30920271 0.92 SMN1; SMN2 (0.35) GRM5SMN1; SMN2EGFRMGLLERBB2
SCHEMBL27247555 0.92 GRM5 (0.35) GRM5SMN1; SMN2EGFRMGLLERBB2
SCHEMBL30920320 0.92 GRM5 (0.35) GRM5SMN1; SMN2EGFRMGLLERBB2
SCHEMBL30920477 0.91 GRM5 (0.35) GRM5SMN1; SMN2EGFRMGLLERBB2
SCHEMBL27247265 0.91 GRM5 (0.35) GRM5SMN1; SMN2EGFRMGLLERBB2
SCHEMBL30920912 0.90 KDM1A (0.33) SMN1; SMN2MGLLPDE10AMAPK1SCD
SCHEMBL27247360 0.90 KDM1A (0.33) SMN1; SMN2MGLLPDE10AMAPK1SCD
SCHEMBL30946117 0.89 GRM5 (0.37) GRM5SMN1; SMN2EGFRMGLLERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 GRM5 690/4885SMN1; SMN2 375/4885EGFR 2037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback